

Using routine prescribing data to identify comorbidities in cancer patients


Chris Brown, Linda Sharp,
Kathleen Bennett, Ian Barron

National Cancer Registry Ireland

[@CStatsAU](#) [@IrishCancerReg](#)

Comorbidities are common

~ 2 in 3 patients



We know it matters

Cancer and Comorbidity

Redefining Chronic Diseases

Karen S. Ogle, M.D.
G. Marie Swanson
Nancy Woods, R.N.
Faouzi Azzouz, M.S.

¹ Department of Family
University,

² Cancer C
Lansing, M

³ Departme
Women's H
University of V

Lost Productivity and Burden of Illness in Cancer Survivors With and Without Other Chronic Conditions

Emily C. Dowling, MHS¹; Neetu Chawla, PhD, MPH²; Laura P. Forsythe, PhD, MPH²; Janet de Moor, PhD, MPH²;
Timothy McNeel, BA³; Heather M. Rozjabek, MPH²; Donatus U. Ekwueme, PhD⁴; and K. Robin Yabroff, PhD, MBA²

DIFFERENTIAL PROGNOSTIC IMPACT OF COMORBIDITY IN HEAD AND NECK CANCER

Olli-Pekka Alho, MD,¹ Kalle Hannula, MD,¹ Antti Luukkala, MD,¹ Heikki Teppo, MD,¹
Petri Koivunen, MD,¹ Saara Kantola, DDS²

¹ Department of Otorhinolaryngology, University of Oulu, P.O. Box 5000, Oulu FIN-90014, Finland.
E-mail: opalho@cc.oulu.fi

² Department of Diagnostics and Oral Medicine, University of Oulu, P.O. Box 5000,
Oulu FIN-90014, Finland


Accepted 7 December 2006

Published online 17 May 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hed.20608

nit
er
8-
c-
ty,
nic
ly,
di-
es
ur-
s.


Impact on survival

Adjusted hazard ratios of comorbidities on all-cause mortality (stratified analyses) SEER data



Cancer registries

Most cancer registries haven't routinely collected data on comorbidities...



...but increasingly have access to sources of in-patient records + community prescribing data.



Measuring comorbidities

Medical history based ICDX / ICDX-CM

Cumulative Illness
Rating Scale (CIRS) 68'

Hierarchical Coexisting
Conditions (HCC) 89'

Index of Co-existent
Disease (ICED) 91'

Elixhauser 98'

Diagnosis-Related
Groups (DRGs) 95'

Kaplan-Feinstein
Classification
(KFC) 74'

ACE-27

Charlson Index 87'


Klabunde

D'Hoore

Ambulatory Care
Groups (ACGs) 91'

Prescription based ATC

Chronic Disease
Scale (CDS) 92' / 95'



Rx-Risk 03'
Rx-Risk-V 03'

Distinct Medication
Classes
(DMC) 01'


RxRisk: Prescription groups

Alcohol dependence	End stage renal disease	Ischaemic heart disease/hypertension	Chronic airways disease
Allergies	Epilepsy	Inflammatory bowel disease	Smoking cessation
Anti-coagulation therapy	Gastric-oesophageal reflux disorder & Ulcer	Liver failure	Systemic corticosteroids
Anti-platelet therapy	Glaucoma	Malignancies	Transplant
Anxiety	Gout	Migraine	Tuberculosis
Arrhythmia	Hepatitis C	Osteoporosis/Pagets	Asthma
Benign prostate hypertrophy	HIV	Pain (Opiates)	liver Disease
Bipolar disorder	Hyperkalaemia	Inflammation/pain	Rheumatoid Arthritis
Chronic heart failure	Hyperlipidemia	Pancreatic insufficiency	Thyroid Disorder
Dementia	Hypertension	Parkinsons disease	Neurogenic Bladder / Urinary Incontinence
Depression	Hypothyroidism	Psoriasis	Ostomy
Diabetes	Angina	Psychotic illness	


Project objective

- Evaluate the utility of using prescribing data to identify comorbidities in ovarian cancer patients in Ireland
 - Using **RxRisk**, **DMC** methods based on prescriptions in the **year prior** to diagnosis.
- Determine prognostic value of estimated comorbidities on:
 - Initial treatment (logistic regression)
 - Overall survival (Cox regression)

Prescription data linkage



All women diagnosed with invasive ovarian cancer (ICD10-C56) between 2001-2010 were linked to health card records




Prescribing history for matched cases

Observed comorbidities


- 1,542 (50%) of the 3,097 incident ovarian cancers had a health cards for a year prior to diagnosis.

	Comorbidity	Incidence	% of cohort
1	Gastric Acid	606	39.4%
2	Hypertension	553	36.0%
3	Antiplat	482	31.4%
4	Hyperlipidaemia	482	31.4%
5	Inflam Pain	433	28.2%
6	Ischaemic heart disease	386	25.1%
7	Pain	353	23.0%
8	Depression	303	19.7%
9	Anxiety	244	15.9%
10	Reactive airways	223	14.5%

Correlation of methods



Association with age



Association with treatment

- Surgery (within year of diagnosis)

	OR	95% CI	AOR	95% CI
RxRisk	0.99	(0.95, 1.03)	1.00	(0.95,1.06)
# Codes	0.99	(0.98, 1.01)	1.00	(0.98,1.02)

- Chemotherapy (within year of diagnosis)

	OR	95% CI	AOR	95% CI
RxRisk	0.98	(0.94,1.02)	0.97	(0.93, 1.02)
# Codes	0.99	(0.98, 1.01)	1.00	(0.98, 1.02)

Association with survival

- Comorbidity adversely affected survival

	HR	95% CI	P-Value
RxRisk	1.026	(1.002, 1.050)	0.032
# Codes	1.010	(1.001, 1.018)	0.026

- Models adjusted for: Marital status, smoking, loco/regional, urban/rural, age.

Parameter	Adjusted HR	95% CI	P-Value
RxRisk	1.028	(1.003, 1.053)	0.027
# Codes	1.008	(0.999, 1.017)	0.079

Specific comorbidities

Modelling all comorbidities simultaneously....

	HR*	95% HR CI*	P-Value*
Depression	1.16	(1.00, 1.34)	0.049
Hyperlipidaemia	1.14	(1.01, 1.29)	0.034
Pain	0.86	(0.75, 0.99)	0.035
Reactive airways	1.28	(1.09, 1.50)	0.0028



*Unstable model subject to colinearity

Summary

Comorbidities can be estimated by the NCRI using routine prescribing data

We observed some association with survival in the Irish ovarian cancer cohort

Acknowledgements

- Staff at **National Cancer Registry of Ireland**, in particular:
 - **The data team** for linkage of GMS records,
 - **Tumour registration officers** for collecting registry data
- **Primary Care Reimbursement Service** for providing the data
- Project funding from **Irish Health Research Board**

Further information

c.brown@ncri.ie

[@CStatsAU](#)